Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
148
-
Total 13F shares, excl. options
-
54,835,912
-
Shares change
-
+2,029,433
-
Total reported value, excl. options
-
$1,532,629,456
-
Value change
-
+$56,326,804
-
Put/Call ratio
-
97.06%
-
Number of buys
-
72
-
Number of sells
-
-67
-
Price
-
$27.95
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2021
175 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2021.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,835,912 shares
of 104,661,494 outstanding shares and own 52.39% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5,393,839 shares), JPMORGAN CHASE & CO (4,433,826 shares), VANGUARD GROUP INC (3,543,094 shares), ALLIANCEBERNSTEIN L.P. (3,353,279 shares), Palo Alto Investors LP (3,201,866 shares), ArrowMark Colorado Holdings LLC (3,163,255 shares), WELLINGTON MANAGEMENT GROUP LLP (2,835,691 shares), FMR LLC (2,776,700 shares), Essex Woodlands Management, Inc. (2,759,950 shares), and Capital World Investors (2,571,102 shares).
This table shows the top 148 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.